BioCentury | Mar 15, 2019
Product Development

Broadening the PARP playing field

...she added. Merck and AZ have started a tumor-agnostic trial of Lynparza. The Phase II LYNK-002...
Items per page:
1 - 1 of 1
BioCentury | Mar 15, 2019
Product Development

Broadening the PARP playing field

...she added. Merck and AZ have started a tumor-agnostic trial of Lynparza. The Phase II LYNK-002...
Items per page:
1 - 1 of 1